Dossier assessment
Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of the benefit assessment
Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Afatinib: added benefit in certain mutations confirmed
Lung cancer patients with Del19 mutation benefit most
Project details
- Project no.
- A15-17
- Commission
- Commission awarded on 15.05.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Afatinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed